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Background: Real-time reverse transcription PCR (rRT-PCR) of sputum samples is com-
monly used to diagnose Middle East respiratory syndrome coronavirus (MERS-CoV) infec-
tion. Owing to the difficulty of extracting RNA from sputum containing mucus, sputum ho-
mogenization is desirable prior to nucleic acid isolation. We determined optimal homoge-
nization methods for isolating viral nucleic acids from sputum.
Methods: We evaluated the following three sputum-homogenization methods: proteinase K 
and DNase I (PK-DNase) treatment, phosphate-buffered saline (PBS) treatment, and N-
acetyl-L-cysteine and sodium citrate (NALC) treatment. Sputum samples were spiked with 
inactivated MERS-CoV culture isolates. RNA was extracted from pretreated, spiked sam-
ples using the easyMAG system (bioMérieux, France). Extracted RNAs were then sub-
jected to rRT-PCR for MERS-CoV diagnosis (DiaPlex Q MERS-coronavirus, SolGent, Korea).
Results: While analyzing 15 spiked sputum samples prepared in technical duplicate, 
false-negative results were obtained with five (16.7%) and four samples (13.3%), respec-
tively, by using the PBS and NALC methods. The range of threshold cycle (Ct) values ob-
served when detecting upE in sputum samples was 31.1-35.4 with the PK-DNase 
method, 34.7-39.0 with the PBS method, and 33.9-38.6 with the NALC method. Com-
pared with the control, which were prepared by adding a one-tenth volume of 1:1,000 di-
luted viral culture to PBS solution, the ranges of Ct values obtained by the PBS and NALC 
methods differed significantly from the mean control Ct of 33.2 (both P <0.0001).
Conclusions: The PK-DNase method is suitable for homogenizing sputum samples prior 
to RNA extraction.
Key Words: MERS coronavirus, Sputum, Homogenization, Nucleic acid extraction, Com-
parison, Proteinase K, DNase
Received: September 17, 2015
Revision received: March 22, 2016
Accepted: May 17, 2016
Corresponding author: Heungsup Sung
Department of Laboratory Medicine, 
University of Ulsan College of Medicine and 
Asan Medical Center, 88 Olympic-ro 43-gil, 
Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-4499
Fax: +82-2-478-0884
E-mail: sung@amc.seoul.kr
Co-corresponding author: Mi-Na Kim 
Department of Laboratory Medicine, 
University of Ulsan College of Medicine and 
Asan Medical Center, 88 Olympic-ro 43-gil, 
Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-4511
Fax: +82-2-478-0884
E-mail: mnkim@amc.seoul.kr
© The Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
INTRODUCTION
Rapid and accurate diagnosis of infection and control measures 
are critical for preventing the spread of Middle East respiratory 
syndrome coronavirus (MERS-CoV) [1]. For laboratory diagnosis 
of MERS-CoV infection, lower respiratory samples are preferred 
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irrespective of the length of time between symptom onset and 
sample collection [2]. Real-time reverse transcription PCR (rRT-
PCR) with sputum samples is commonly used to diagnose 
MERS-CoV infection.
If a negative result is obtained for patients with a high index of 
suspicion for MERS-CoV infection, additional samples should be 
collected and tested [3]. A series of negative results does not 
rule out the possibility of MERS-CoV infection [1, 3]. Possible 
explanations for false-negative MERS-CoV test results include 
low viral load very early or late in the illness, inadequate sputum 
samples due to poor sample collection from patients with dry 
cough or no cough, inappropriate sample handling or shipping, 
and technical issues, such as viral genome mutation or PCR in-
hibition [3]. Sufficient nucleic acid extraction and the removal of 
substances that inhibit amplification are critical factors influenc-
ing the detection of MERS-CoV by rRT-PCR [4]. However, rRT-
PCR of sputum samples yields conflicting results owing to the 
difficulty of extracting RNA from sputum containing mucus. 
Many reports have indicated that lower respiratory samples 
such as bronchoalveolar lavage (BAL) fluid and sputum contain 
the highest viral loads [3, 5-7]. However, one report indicated 
that no significant difference occurred in viral load cycle thresh-
old (Ct) values between sputa and nasopharyngeal aspirates 
(NPAs) [8]. For this reason, sputum sample homogenization is 
desirable prior to isolating nucleic acids for MERS-CoV rRT-PCR. 
In this study, we compared three different sputum homogeniza-
tion methods and identified an optimal homogenization method 
prior to the nucleic acid isolation from sputum samples.
METHODS
1. Sputum quality
Forty-eight consecutive sputum samples sent to the laboratory 
for MERS-CoV rRT-PCR testing were evaluated in terms of the 
number of white blood cells, squamous epithelial cells, and cili-
ated columnar epithelial cells. The sputum samples were 
graded by using Murray and Washington’s grading system [9].
2. Preparation of virus-spiked sputum samples
An inactivated viral culture of MERS-CoV was provided by the 
Division of Respiratory Viruses (Center for Infectious Diseases, 
Korean National Institute of Health, Korean Center for Disease 
Control). The Korean National Institute of Health did not dis-
close the exact titer of the cultured MERS-CoV. Since other viral 
respiratory pathogens and bacterial pathogens should be con-
sidered during diagnosis [2], we evaluated whether the three 
homogenization methods have an adverse impact on the detec-
tion of other respiratory viruses. For this reason, we evaluated 
three homogenization methods using NPA samples that were 
found to contain various respiratory viruses using the Anyplex II 
RV16 Detection kit (Seegene, Seoul, Korea). Next, we evaluated 
the three homogenization methods using sputum samples 
spiked with a 1:10 or 1:1,000 dilution of viral culture mixed with 
an identical volume of sputum. Finally, we evaluated each ho-
mogenization method using virus-spiked sputum samples pre-
pared by adding one volume of 1:100 diluted inactivated viral 
culture to nine volumes of clinical sample (i.e., sputum or BAL).
3. Sputum-homogenization methods
Sputum samples were pretreated by using one of three meth-
ods. The first method involved proteinase K and DNase I treat-
ment (PK-DNase), as recommended by the NucliSENS easy-
MAG protocol (bioMérieux SA, Marcy-l’Etoile, France). One 
hundred microliters of proteinase K (1 mg proteinase K/1 mL 
proteinase K buffer; Promega, Madison, WI, USA) was added to 
100 µL of sample and incubated for 15 min at 55°C. The sam-
ples were mixed by vortexing every 5 min. Subsequently, a 20-
µL of DNase I solution (1 U/µL) was added for every 100 µL of 
sample, followed by incubation at 37°C for 30 min. In the sec-
ond method, sputum samples were mixed with an equal volume 
of phosphate-buffered saline (PBS). In the third method, the 
sputum samples were mixed with an equal volume of N-acetyl-
L-cysteine (NALC) in sodium citrate solution (prepared by dis-
solving 0.5g NALC in each 100 mL of 1.47% sodium citrate so-
lution). Following the second and third methods, the samples 
were mixed by vortexing for 1 min.
4. RNA extraction and MERS-CoV rRT-PCR testing
RNA was extracted as described previously [10] by using the 
NucliSENS easyMAG system (bioMérieux SA, Marcy-l’Etoile, 
France). RNA from each pretreated sample (500 µL) was eluted 
in a 50-μL volume. Extracted RNA was tested by rRT-PCR using 
Anyplex II RV16 Detection kit (Seegene) for the preliminary test, 
or by rRT-PCR using DiaPlexQ MERS Virus Detection kit (Sol-
Gent, Daejeon, Korea) with Bio-Rad CFX96 instrument (Bio-
Rad, Hercules, CA, USA). The sequences of the primers and 
probes used with the DiaPlexQ kit covered the same general re-
gions of the upE and ORF1a transcripts.
5. Statistical analysis
Quantitative results were expressed as mean±SD, and groups 
were compared by using the one-sample t-test. P values <0.05 
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were considered statistically significant. MedCalc software ver-
sion 16.2 (MedCalc Software bvba, Ostend, Belgium) was used 
for statistical analysis.
RESULTS
According to Murray and Washington’s grading system [9], 
among the 48 sputum samples tested, 18 (37.5%) belonged to 
group 1, 6 (12.5%) belonged to group 3, 2 (4.2%) belonged to 
group 4, 5 (10.4%) belonged to group 5, and 17 (35.4%) be-
longed to group 6. Thirty-two samples (66.7%), including 20 
from groups 1-3, harbored a detectable quantity of ciliated co-
lumnar epithelial cells. Seventeen samples (35.4%) harbored 
identifiable proteinaceous mucous threads (viewed via light mi-
croscopy).
The efficacies of the three homogenization methods tested 
with NPA samples are summarized in Table 1. For DNA respira-
tory viruses (such as adenovirus and human bocavirus), PK-
DNase treatment caused a slight increase in Ct values com-
pared with PBS or NALC treatment. When we additionally tested 
six adenovirus-positive NPAs and five bocavirus-positive NPAs, 
the Ct values obtained following PBS preparation were 1.50-
6.18 (median 5.42) and 1.60-7.61 (median 3.4) lower, respec-
tively, than those obtained following PK-DNase preparation. 
Among the 10 samples derived from RNA respiratory viruses, 
the minimum Ct values resulted from PK-DNase treatment of 
three samples, PBS treatment of five samples, and NALC treat-
ment of two samples.
Using identical volumes of sputum and inactivated viral cul-
ture diluted 1:10 or 1:1,000, the effects of each homogenization 
method on the MERS-CoV rRT-PCR results were evaluated (Ta-
ble 2). Using a 1:10 dilution of inactivated viral culture, all sam-
ples treated with PK-DNase exhibited lower Ct values than those 
subjected to PBS or NALC treatment. The differences in Ct val-
ues between samples treated with PK-DNase or PBS were 5.4-
7.8 for upE and 4.4-6.8 for ORF1a, while those for samples 
treated with PK-DNase or NALC were 4.7-5.8 for upE and 4.4-
5.6 for ORF1a. Using the same volume of a 1:1,000 dilution of 
inactivated viral culture, one purulent sputum sample showed a 
false-negative result after PBS treatment. The Ct values of the 
other two sputum samples were similar following PK-DNase, 
PBS, and NALC treatments.
Using a one-tenth volume of a 1:1,000 dilution of inactivated 
viral culture (to simulate conditions comparable to those of real 
clinical samples), the effects of each method on the MERS-CoV 
rRT-PCR results were evaluated (Table 3). Among the three 
sputum samples, false-negative results were detected in two 
samples following PBS treatment and in three samples after 
NALC treatment (Table 3). Although the Ct values after PK-DN-
ase treatment tended to be lower than those following PBS or 
Table 1. Cycle threshold (Ct) values following three homogenization methods used before Anyplex II RV16 detection of respiratory viruses 
in nasopharyngeal aspirates by rRT-PCR
Homogenization by
Respiratory virus (N)
ADV (1) BoV (2) INF A (2) RhinoV (1) CoV 229E/NL63 (2) CoV OC43 (2) RSV (2) hMPV (1)
PK-DNase I 35.6 26.5/29.9 20.8/42.6 33.4 31.2/42.7 32.7/37.4 35.8/40.4 42.2
PBS 34.1 21.6/28.3 19.8/41.9 31.7 33.2/44.3 35.8/35.4 37.0/37.3 38.3
NALC-sodium citrate 33.1 22.4/28.6 21.1/42.0 32.3 30.8/45.1 35.0/35.6 36.3/35.1 39.2
Abbreviations: rRT-PCR, Real-time reverse transcription PCR; PK, proteinase K; PBS, phosphate-buffered saline; NALC, N-acetyl-L-cysteine; ADV, adenovi-
rus; BoV, human bocavirus; INF A, influenza virus A; RhinoV, rhinovirus; CoV, human coronavirus; RSV, respiratory syncytial virus; hMPV, human metapneu-
movirus.
Table 2. Cycle threshold (Ct) values observed with three homogenization methods following mixture of identical volumes of a 1:10 or 
1:1,000 dilution of inactivated MERS-CoV culture with sputum samples
Homogenization by N
1:10 diluted cell culture 1:1,000 diluted cell culture
upE ORF1a upE ORF1a
PK-DNase 1 3 17.6/20.9/20.2* 18.1/21.1/20.4 34.2/34.6/34.3 35.7/35.6/35.8
PBS 3 23.4/26.3/28.0 22.5/26.1/27.2 34.6/34.4/Neg 35.3/35.8/Neg
NALC-sodium citrate 3 23.0/25.6/26.0 22.5/25.6/26.0 35.6/33.0/34.9 37.6/34.1/36.1
*The 3 sputum samples shown include 1 saliva-like sputum sample, 1 non-purulent sputum sample, and 1 purulent sputum sample, with the results shown 
in this order.
Abbreviations: NALC, N-acetyl-L-cysteine; Neg, negative; PBS, phosphate-buffered saline; PK, proteinase K. 
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NALC treatment, the values for BAL samples did not differ 
markedly depending on the homogenization method used. 
To assess statistical significance, we tested 15 additional 
spiked samples, which were prepared by adding a one-tenth 
volume of 1:1,000 diluted viral culture (Table 4). Among the 15 
spiked sputum samples prepared in duplicate (30 total sam-
ples), false-negative results were detected in five samples 
(16.7%) using the PBS method and in four samples (13.3%) 
using the NALC method. The ranges of Ct values for upE from 
sputum samples were 31.1-35.4 using the PK-DNase method, 
34.7-39.0 using the PBS method, and 33.9-38.6 using the 
NALC method. Compared with the control, which were pre-
pared by adding a one-tenth volume of 1:1,000 diluted viral 
culture to PBS solution, the ranges of Ct values following the 
PBS and NALC methods significantly differed from the mean Ct 
value (33.2) of the control (both P <0.0001).
DISCUSSION
For the extraction of MERS-CoV RNA from sputum sample, ho-
mogenization of sputum by PK-DNase I treatment was superior 
to treatment with PBS or NALC and sodium citrate. Proteinase 
K is a serine protease that exhibits broad cleavage specificity 
[11]. The enzyme cleaves peptide bonds adjacent to carboxylic 
group of aliphatic and aromatic amino acids and is useful for 
the general digestion of proteins in biological samples. More-
over, proteinase K degrades any RNases present in samples, 
preventing RNA degradation. Viral nucleic acids are protected 
from DNase I degradation by the viral protein capsids, although 
some enveloped viruses may be lost [12]. The genomes of DNA 
viruses such as adenovirus and bocavirus can be affected by 
proteinase K and DNase I, possibly owing to the digestion of vi-
ral capsid proteins by proteinase K and subsequent degradation 
of genomic DNA by DNase I. 
Confirmation of probable or suspected MERS-CoV infection 
based on clinical and epidemiological criteria can only be ac-
complished through laboratory testing. However, other viral re-
spiratory pathogens and bacterial pathogens should be consid-
ered during diagnosis [3]. When using lower respiratory samples 
originally earmarked for MERS-CoV testing, other viral respira-
tory pathogens should be tested for routine diagnostic pro-
cesses. Because the ability to detect DNA respiratory viruses 
can be reduced by DNase I treatment, proteinase K treatment 
alone is worth considering for the routine detection of respiratory 
viruses from sputum samples.
The United States Centers for Disease Control and Prevention 
recommends that respiratory samples be extracted by using ei-
ther the NucliSENS easyMAG system or MagNA Pure Compact 
Nucleic Acid Isolation kit [2]. Sputum samples categorized into 
groups 4-5 according to Murray and Washington’s grading sys-
tem [9] usually cannot undergo automated extraction owing to 
high viscosity and, thus, require a pre-homogenization process. 
Table 3. Cycle threshold (Ct) values for triplicate sputum and bronchoalveolar lavage (BAL) samples following processing using three differ-
ent homogenization methods
Homogenization by N*
Sputum BAL
upE ORF1a upE ORF1a
PK-DNase 1 3 34.9/36.3/34.0 35.0/34.9/35.4 34.1/33.9/34.4 34.6/34.0/35.1
PBS 3 Neg/37.9/Neg Neg/Neg/Neg 34.1/33.9/33.7 34.8/34.4/35.0
NALC-sodium citrate 3 Neg/Neg/Neg Neg/Neg/Neg 35.0/34.6/34.3 35.7/35.8/35.5
*Three different sputum and bronchoalveolar lavage samples were included, and results are provided in this order.
Abbreviations: NALC, N-acetyl-L-cysteine; Neg, negative; PBS, phosphate-buffered saline; PK, proteinase K.
Table 4. Cycle threshold (Ct) values for upE measured with duplicate sputum samples following processing using three homogenization 
methods
Homogenization by Sample N (Results N) N of positive results (%)
Ct value from positive 
samples, mean±SD (range)
P value*
PK-DNase 1 15 (30) 30 (100) 33.6±1.3 (31.1-35.4) 0.11
PBS 15 (30) 25 (83.3) 35.8±1.2 (34.7-39.0) <0.0001
NALC-sodium citrate 15 (30) 26 (86.7) 35.7±1.5 (33.9-38.6) <0.0001
*The significance level was calculated by using the one-sample t-test. The null hypothesis was that the test mean was equal to the control mean of 33.2.
Abbreviations: NALC, N-acetyl-L-cysteine; PBS, phosphate-buffered saline; PK, proteinase K.
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Treatment with PBS or NALC and sodium citrate occasionally 
produces false-negative results with purulent sputum. Adding 
PBS and mixing via vortexing are necessary to culture respira-
tory viruses from sputum, and this procedure offers the advan-
tage of involving minimum sample handling. However, thor-
oughly homogenizing thick or purulent sputum using this 
method is problematic. Because viral isolation by cell culture is 
not recommended for the routine confirmation of cases of 
MERS-CoV [2, 3], the PBS plus vortexing method for processing 
sputum samples is not suitable for detecting MERS-CoV by rRT-
PCR. Previously, it was reported that NALC and sodium citrate 
treatment (without NaOH) did not damage mycobacterial 
mRNA or rRNA in sputum samples [13]. NALC and sodium ci-
trate solutions are readily available in clinical microbiology labo-
ratories. Treatment with NALC and sodium citrate solution re-
sulted in complete homogenization of sputum samples, includ-
ing purulent sputum. However, this method is not suitable for 
detecting RNA targets in purulent sputum. Because proteinase 
K treatment requires heat inactivation of potential pathogens 
(incubation for 15 min at 55°C), this method offers additional 
laboratory safety. 
Only 10% of sputum samples sent for MERS-CoV rRT-PCR 
testing were clinically relevant in terms of bacterial culture 
(group 5 according to Murray and Washington’s grading system 
[9]). Among patients infected with MERS-CoV, a dry cough is 
more common than a productive cough [16, 17]. Therefore, 
optimum sample collection is not feasible for patients unable to 
produce sputum. However, two thirds of sputum samples in our 
study contained identifiable ciliated columnar epithelial cells. 
Dipeptidyl peptidase 4, the human receptor for MERS-CoV [16], 
is expressed in type I and II alveolar cells, ciliated or non-ciliated 
bronchial epithelial cells, and bronchial submucosal glands [18, 
19]. Although it is difficult to obtain high-quality sputum from 
patients with no cough or a dry cough, obtaining and testing 
sputum samples containing ciliated columnar epithelial cells is 
recommended, if possible.
Our study has several limitations. First, it was performed by 
using spiked sputum samples; thus, our results may differ from 
those obtained by using authentic MERS-CoV-positive samples. 
However, the spiked sputum samples were similar to real spu-
tum samples, as they were produced by adding a one-tenth vol-
ume of spiked viral solution to total sputum samples. Second, 
we tested a relatively small number of sputum samples under 
each test condition. Therefore, our findings should be confirmed 
by additional, larger studies.
In conclusion, the PK-DNase I treatment is suitable for the 
homogenization of sputum prior to RNA extraction for MERS-
CoV rRT-PCR detection. Furthermore, adequate sputum ho-
mogenization prior to the isolation of nucleic acids is critical for 
accurate diagnosis of MERS-CoV infection.
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